+

WO2007030698A3 - Materiaux et procedes de fabrication de microstructures et de nanostructures isolees presentant une fonctionnalite chimique - Google Patents

Materiaux et procedes de fabrication de microstructures et de nanostructures isolees presentant une fonctionnalite chimique Download PDF

Info

Publication number
WO2007030698A3
WO2007030698A3 PCT/US2006/034997 US2006034997W WO2007030698A3 WO 2007030698 A3 WO2007030698 A3 WO 2007030698A3 US 2006034997 W US2006034997 W US 2006034997W WO 2007030698 A3 WO2007030698 A3 WO 2007030698A3
Authority
WO
WIPO (PCT)
Prior art keywords
structures
nano
materials
methods
chemical functionality
Prior art date
Application number
PCT/US2006/034997
Other languages
English (en)
Other versions
WO2007030698A2 (fr
Inventor
Joseph M Desimone
Jason P Rolland
Edward T Samulski
Benjamin W Maynor
Ginger Denison Rothrock
Original Assignee
Univ North Carolina State
Joseph M Desimone
Jason P Rolland
Edward T Samulski
Benjamin W Maynor
Ginger Denison Rothrock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State, Joseph M Desimone, Jason P Rolland, Edward T Samulski, Benjamin W Maynor, Ginger Denison Rothrock filed Critical Univ North Carolina State
Priority to US11/594,023 priority Critical patent/US9040090B2/en
Publication of WO2007030698A2 publication Critical patent/WO2007030698A2/fr
Publication of WO2007030698A3 publication Critical patent/WO2007030698A3/fr
Priority to US14/704,047 priority patent/US9902818B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ceramic Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Selon l'invention, des particules nanométriques sont formées dans des formes et des dispersions de tailles uniformes prédéterminées. Les particules peuvent comprendre des agents thérapeutiques et des agents diagnostiques. Les particules nanométriques forment des dispositifs d'administration de médicaments, des systèmes de traitement, des systèmes de diagnostic et peuvent comprendre des structures imprégnées moléculaires pour former des systèmes analytiques. En outre, les particules nanométriques peuvent former des molécules fonctionnelles artificielles par simulation de groupes fonctionnels de molécules modèles à imprégnation moléculaire.
PCT/US2006/034997 2003-12-19 2006-09-07 Materiaux et procedes de fabrication de microstructures et de nanostructures isolees presentant une fonctionnalite chimique WO2007030698A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/594,023 US9040090B2 (en) 2003-12-19 2006-11-07 Isolated and fixed micro and nano structures and methods thereof
US14/704,047 US9902818B2 (en) 2003-12-19 2015-05-05 Isolated and fixed micro and nano structures and methods thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US71496105P 2005-09-07 2005-09-07
US60/714,961 2005-09-07
US73422805P 2005-11-07 2005-11-07
US60/734,228 2005-11-07
US76280206P 2006-01-27 2006-01-27
US60/762,802 2006-01-27
US79987606P 2006-05-12 2006-05-12
US60/799,876 2006-05-12

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/583,570 Continuation-In-Part US8263129B2 (en) 2003-12-19 2004-12-20 Methods for fabricating isolated micro-and nano-structures using soft or imprint lithography
PCT/US2004/042706 Continuation-In-Part WO2005101466A2 (fr) 2003-12-19 2004-12-20 Procede de fabrication de microstructures et de nanostructures au moyen de la lithographie molle ou d'impression

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/023722 Continuation-In-Part WO2007024323A2 (fr) 2003-12-19 2006-06-19 Procedes, systemes et materiaux de fabrication de nanoparticules
US11/594,023 Continuation-In-Part US9040090B2 (en) 2003-12-19 2006-11-07 Isolated and fixed micro and nano structures and methods thereof

Publications (2)

Publication Number Publication Date
WO2007030698A2 WO2007030698A2 (fr) 2007-03-15
WO2007030698A3 true WO2007030698A3 (fr) 2009-04-30

Family

ID=37836508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034997 WO2007030698A2 (fr) 2003-12-19 2006-09-07 Materiaux et procedes de fabrication de microstructures et de nanostructures isolees presentant une fonctionnalite chimique

Country Status (1)

Country Link
WO (1) WO2007030698A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040090B2 (en) 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
WO2009049299A1 (fr) 2007-10-12 2009-04-16 Liquidia Technologies, Inc. Système et procédé de production de particules et de films à motifs
CA2734864A1 (fr) * 2008-08-21 2010-02-25 Innova Dynamics, Inc. Surfaces et revetements ameliores, et procedes associes
AU2010217957B2 (en) 2009-02-26 2015-08-13 Liquidia Technologies, Inc. Interventional drug delivery system and associated methods
EP2454011A2 (fr) * 2009-07-13 2012-05-23 The University of North Carolina At Chapel Hill Particules d'aérosol modifiées et procédés associés
US10170764B2 (en) 2010-06-30 2019-01-01 Semiconductor Energy Laboratory Co., Ltd. Method for manufacturing ultra small particle, positive electrode active material of second battery using the method for manufacturing ultra small particle and method for manufacturing the same, and secondary battery using the positive electrode active material and method for manufacturing the same
IL225219A (en) * 2013-03-14 2017-08-31 Micro Tag Temed Ltd A magnetic resonance facility for the detection and detection of tiny quantities of specific materials quickly and efficiently
US10786569B2 (en) * 2015-07-31 2020-09-29 Wei Wu Lithographically defined nanoparticles for microwave absorption
CN111426767B (zh) * 2020-04-21 2022-07-12 沈阳信达泰康医药科技有限公司 一种磁性纳米复合材料及其制备和在食品检测中的应用
CN111909330B (zh) * 2020-07-07 2022-10-28 重庆迈德凯医药有限公司 玉米醇溶蛋白磁性分子印迹聚合物以及电化学传感器及其应用
CN116393114A (zh) * 2023-05-26 2023-07-07 西安交通大学 一种爆米花状轻质美罗培南分子印迹磁性纳米材料及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5869103A (en) * 1994-06-18 1999-02-09 Danbiosyst Uk Limited Polymer microparticles for drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5869103A (en) * 1994-06-18 1999-02-09 Danbiosyst Uk Limited Polymer microparticles for drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIANG ET AL.: "A lost-Wax Approach to Monodisperse Colloids and Their Crystals,", SCIENCE, vol. 291, 2001, pages 453, XP055034599, DOI: doi:10.1126/science.291.5503.453 *

Also Published As

Publication number Publication date
WO2007030698A2 (fr) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2007030698A3 (fr) Materiaux et procedes de fabrication de microstructures et de nanostructures isolees presentant une fonctionnalite chimique
WO2008140583A3 (fr) Nanotubes de nitrure de bore fonctionnalisés
WO2008039254A3 (fr) Nanoparticules d'arn et nanotubes
ATE467649T1 (de) Molekulare prägungen zur erkennung in wässrigen medien, herstellungsverfahren dafür und verwendungen davon
WO2008129106A3 (fr) Nanoparticules comprenant une cyclodextrine et une molécule biologiquement active et leurs applications
WO2008045486A3 (fr) Compositions de nanoparticules pour la mise en place contrôlée d'acides nucléiques
AU2010279931B2 (en) Composition and process for production thereof
WO2008151049A3 (fr) Nanoparticules fonctionnalisées par des acides nucléiques pour des applications thérapeutiques
EP1731550A4 (fr) Nouveau fullerène soluble dans l'eau, procédé servant à produire celui-ci et générateur d'oxygène actif contenant le fullerène
ATE494297T1 (de) Membranproteinimmobilisierung auf einem träger mit einem amphiphilen molekül
WO2007019478A3 (fr) Liberation de medicaments par des implants comprenant des monocouches auto-assemblees (sam) sam therapeutiques
FR2888836B1 (fr) Fines particules d'alpha-alumine, leur procede de production, corps en alpha-alumine et son procede de production, et abrasif comprenant l'alpha-alumine
WO2008106503A3 (fr) Nanoparticules organiques pharmaceutiques de taille et de forme discrètes
WO2017210666A3 (fr) Nanoparticules fonctionnalisées pour l'administration intracellulaire de molécules biologiquement actives et leurs procédés de fabrication et d'utilisation
WO2006133707A3 (fr) Polytherapie contre le cancer et kit de composants associe
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
WO2011143201A3 (fr) Administration de médicaments combinatoire ratiométrique
FR2925060B1 (fr) Procede de preparation d'un materiau polymere transparent comprenant un polycarbonate thermoplastique et des nanoparticules minerales.
WO2009098404A8 (fr) Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation
WO2009058443A3 (fr) Nanostructures de carbone hydrosolubles à fonction polyol
FR2920320B1 (fr) Procede pour la production de fluorapatite, fluorapatite et appareil d'adsorption.
Kam et al. Nano-and microfabrication for overcoming drug delivery challenges
WO2006111493A3 (fr) Formulations de pigments
WO2006137856A3 (fr) Procede de production de nanoparticules et de microparticules par concentration d'un agent ternaire produisant une immiscibilite induite par alteration de temperature
ATE363498T1 (de) Leuchtsubstanz- oder kontrastmittelhaltige latexpolymerpartikel und deren herstellungsverfahren

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11594023

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06814338

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载